Mauro E, Rodriguez-Peralvarez M, DAlessio A, Crespo G, Pinero F, De Martin E
Liver Int. 2024; 45(4):e16142.
PMID: 39494583
PMC: 11891387.
DOI: 10.1111/liv.16142.
Tang S, Wu Y, Lin Z, Chen Q, Luo C, Li Y
Front Oncol. 2024; 14:1425292.
PMID: 38903723
PMC: 11188428.
DOI: 10.3389/fonc.2024.1425292.
Kim S, Hwang S, Song G, Ahn C, Moon D, Ha T
Surg Today. 2024; 55(1):99-109.
PMID: 38869691
DOI: 10.1007/s00595-024-02879-x.
Chabert S, Iesari S, Dahlqvist G, Komuta M, Baldin P, Favi E
Diagnostics (Basel). 2024; 14(9).
PMID: 38732309
PMC: 11083058.
DOI: 10.3390/diagnostics14090894.
Zhou Z, Liu Q, Liu J, Li W, Cao S, Xu J
Heliyon. 2024; 10(9):e30622.
PMID: 38726103
PMC: 11079398.
DOI: 10.1016/j.heliyon.2024.e30622.
No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Living Donor Liver Transplantation.
Yang G, Hwang S, Ahn C, Moon D, Ha T, Song G
Ann Transplant. 2024; 29:e942767.
PMID: 38439530
PMC: 10924426.
DOI: 10.12659/AOT.942767.
The Role of PIVKA-II as a Predictor of Early Hepatocellular Carcinoma Recurrence-Free Survival after Liver Transplantation in a Low Alpha-Fetoprotein Population.
Devillers M, Pluimers J, van Hooff M, Doukas M, Polak W, de Man R
Cancers (Basel). 2024; 16(1).
PMID: 38201435
PMC: 10778448.
DOI: 10.3390/cancers16010004.
Incorporation of protein induced by vitamin K absence or antagonist-II into transplant criteria expands beneficiaries of liver transplantation for hepatocellular carcinoma: a multicenter retrospective cohort study in China.
Wang K, Dong L, Lu Q, Yang Z, Fan X, Gao F
Int J Surg. 2023; 109(12):4135-4144.
PMID: 37988413
PMC: 10720805.
DOI: 10.1097/JS9.0000000000000729.
The yesterday, today and tomorrow of liver transplant.
Singh K, Kaistha S, Jain R, Khurana S
Med J Armed Forces India. 2023; 79(6):638-644.
PMID: 37981927
PMC: 10654371.
DOI: 10.1016/j.mjafi.2023.08.012.
Donor sex and donor-recipient sex disparity do not affect hepatocellular carcinoma recurrence after living donor liver transplantation.
Oh R, Hwang S, Song G, Ahn C, Moon D, Ha T
Ann Surg Treat Res. 2023; 105(3):133-140.
PMID: 37693289
PMC: 10485355.
DOI: 10.4174/astr.2023.105.3.133.
Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights.
Yu J, Park R, Kim R
J Hepatocell Carcinoma. 2023; 10:1105-1127.
PMID: 37483311
PMC: 10362916.
DOI: 10.2147/JHC.S341195.
Quantitative Prediction of Posttransplant Hepatocellular Carcinoma Prognosis Using ADV Score: Validation with Korea-Nationwide Transplantation Registry Database.
Park G, Hwang S, You Y, Choi Y, Kim J, Joo D
J Gastrointest Surg. 2023; 27(7):1353-1366.
PMID: 37039979
DOI: 10.1007/s11605-023-05670-4.
Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma.
Villalba-Lopez F, Saenz-Mateos L, Sanchez-Lorencio M, De La Orden-Garcia V, Alconchel-Gago F, Cascales-Campos P
Sci Rep. 2023; 13(1):5621.
PMID: 37024609
PMC: 10079651.
DOI: 10.1038/s41598-023-32879-9.
Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
Sekiguchi S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K
Cancer Rep (Hoboken). 2022; 5(11):e1613.
PMID: 35302279
PMC: 9675392.
DOI: 10.1002/cnr2.1613.
Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma.
Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J
Front Oncol. 2021; 11:726213.
PMID: 34900676
PMC: 8660097.
DOI: 10.3389/fonc.2021.726213.
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma.
Lee S, Lee S, Jang J, Bae S, Choi J, Yoon S
Int J Mol Sci. 2021; 22(19).
PMID: 34638613
PMC: 8508906.
DOI: 10.3390/ijms221910271.
Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review.
Toniutto P, Fumolo E, Fornasiere E, Bitetto D
J Clin Med. 2021; 10(17).
PMID: 34501381
PMC: 8432180.
DOI: 10.3390/jcm10173932.
Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N
Gastroenterology. 2021; 161(5):1502-1512.
PMID: 34331914
PMC: 8545832.
DOI: 10.1053/j.gastro.2021.07.033.
Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria.
Alim A, Erdogan Y, Dayangac M, Yuzer Y, Tokat Y, Oezcelik A
Cancer Control. 2021; 28:10732748211011960.
PMID: 33926242
PMC: 8204628.
DOI: 10.1177/10732748211011960.
Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis.
Kim K, Kim T, Kim T, Seong J
J Hepatocell Carcinoma. 2021; 8:35-44.
PMID: 33604314
PMC: 7886258.
DOI: 10.2147/JHC.S290197.